New biomarker data from BEXMAB study at EHA2023

Faron Pharmaceuticals Oy (“Faron” or “the Company”)  Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress Bexmarilimab mode of action in AML/MDS supported with durable Clever-1 target engagement in bone marrow, with increases observed in T and NK cells and antigen presentation Clinical activity across indications, with objective responses in 5 … Read more